🇺🇸 Octreotide Injection in United States

37 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 37

Most-reported reactions

1. Product Use In Unapproved Indication — 6 reports (16.22%)
2. Diarrhoea — 5 reports (13.51%)
3. Product Use Issue — 5 reports (13.51%)
4. Death — 3 reports (8.11%)
5. Drug Ineffective For Unapproved Indication — 3 reports (8.11%)
6. Hyperhidrosis — 3 reports (8.11%)
7. Inappropriate Schedule Of Drug Administration — 3 reports (8.11%)
8. Malignant Neoplasm Progression — 3 reports (8.11%)
9. Multi-Organ Failure — 3 reports (8.11%)
10. Necrotising Colitis — 3 reports (8.11%)

Source database →

Frequently asked questions

Is Octreotide Injection approved in United States?

Octreotide Injection does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Octreotide Injection in United States?

Centre Hospitalier Universitaire, Amiens is the originator. The local marketing authorisation holder may differ — check the official source linked above.